Nirogyone Therapeutics

Nirogyone Therapeutics is a pre-clinical stage biotechnology company dedicated to developing disease-modifying therapies for neurodegenerative disorders. The company's primary focus is on synucleinopathies, such as Parkinson's disease, where it utilizes a proprietary platform to identify small molecules that selectively target and neutralize toxic alpha-synuclein oligomers. By preventing the aggregation and spread of these toxic proteins, Nirogyone aims to halt disease progression rather than just managing symptoms. Headquartered in Bangalore, India, the company leverages advanced computational and biophysical techniques to advance its pipeline of neuroprotective candidates. The firm has been recognized for its innovation through various national entrepreneurship awards and support from major Indian biotech incubators.